Welcome to SARomics Biostructures

Here we present company news & various activities and discuss how we help customers accelerate their lead discovery projects!

2023 – Another Successful Year

The examples in this post demonstrate some representative projects and company business development activities in 2023. The scientific part shows the applications of the three main areas of our expertise: X-ray crystallography, NMR spectroscopy, and integrated drug discovery.

Read More

News update June 2023

We're sharing here the latest company updates. They include a new publication, information about Lund Spring Symposium, and our expected move to new facilities at a new building at Medicon Village.   

Read More

Aqilion secures a strategic research alliance with Merck worth up to € 950 million

First-in-class TAK1 kinase inhibitors were designed in a hit-to-lead program run in close cooperation between three partners, SARomics Biostructures, Red Glead Discovery, and Aqilion. This was made possible by an integrated approach, a fast design-make-test-analyze cycle, and applying structure-based drug design, compound synthesis, and evaluation.

Read More